Application of chlorogenic acid in preparation of medicines for treating pathologic jaundice

A technology of pathological jaundice and chlorogenic acid, applied in the field of biomedicine, to achieve the effect of inhibiting the release and promoting the biosynthesis of glutathione

Inactive Publication Date: 2015-07-01
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported that chlorogenic acid has a variety of pharmacological

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chlorogenic acid in preparation of medicines for treating pathologic jaundice
  • Application of chlorogenic acid in preparation of medicines for treating pathologic jaundice
  • Application of chlorogenic acid in preparation of medicines for treating pathologic jaundice

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0024] Example 1 In vivo pharmacodynamic experiment of chlorogenic acid on pathological jaundice

[0025] 1. Experimental materials and methods

[0026] 1.1 Experimental animals

[0027] 65 clean-grade adult SD rats, half male and half male, weighing 200g~230g

[0028] 1.2 Experimental drugs and reagents

[0029] Chlorogenic acid and phenobarbital sodium injection (In the experiment, chlorogenic acid or phenobarbital sodium can be dissolved in physiological saline to make a series of chlorogenic acid and phenobarbital sodium with different concentrations Intraperitoneal injection for use), total bilirubin determination kit, direct bilirubin determination kit, glutathione determination kit, and one-tenth electronic balance.

[0030] 1.3 Establishment of animal model and group administration

[0031] In this example, acetophenazine (APH) was used as a model drug to construct a rat model of hemolytic jaundice. This model is also a common model for studying neonatal hemolytic jaundice at hom...

Example Embodiment

[0060] Example 2

[0061] Using chlorogenic acid as an effective ingredient, adding one or more pharmaceutically acceptable pharmaceutical excipients to prepare medicines of different dosage forms such as oral preparations, injection preparations or external transdermal administration preparations. Control the content of chlorogenic acid in each preparation unit of the obtained medicine to be 1-3000mg.

[0062] The in vivo pharmacodynamic experiment of chlorogenic acid on pathological jaundice was carried out according to the experimental method described in Example 1. The difference is that the method of administration was changed to intramuscular injection, intravenous injection and gastric gavage respectively for experiment. The results show that the above four methods of administration can effectively reduce α-GST, ALT, AST, direct bilirubin and indirect bilirubin in the serum of pathological jaundice model mice, and promote the synthesis of glutathione in experimental group m...

Example Embodiment

[0102] Example 3: Preparation of freeze-dried powder injection with chlorogenic acid

[0103] 1. Extraction of chlorogenic acid:

[0104] The chlorogenic acid raw material used in this example is obtained by extraction and purification from burdock seeds, with a purity of 99.44%.

[0105] 2. Preparation of chlorogenic acid freeze-dried powder injection

[0106] 2.1 Prescription:

[0107]

[0108] Add the above prescription to the water for injection, stir until it is completely dissolved, adjust the pH, filter with a 0.22μm sterile microporous membrane, and make a total of 2000 2ml powder injections according to the usual operation of sterile freeze-dried powder injections, each Contains 50mg of chlorogenic acid.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a chlorogenic acid in preparation of medicines for treating pathologic jaundice, and belongs to the field of biological medicines. The medicines prepared from the chlorogenic acid as an active component are capable of powerfully promoting biosynthesis of glutathione, so as to effectively play a role in stabilizing a red cell membrane and inhibit release of bilirubin (indirect bilirubin), and simultaneously are capable of recovering the injured liver function and effectively reducing the activity of alpha-glutathione-s-transferase (alpha-GST), alanine aminotransferase (ALT) and aspartic transaminase, so as to promote transformation of the indirect bilirubin into direct bilirubin and drainage through the liver and biliary tracts. Therefore, the content of total bilirubin and indirect bilirubin in the blood is effectively reduced; and new means and choice are provided for drug treatment of pathologic jaundice, especially hemolytic jaundice.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the use of chlorogenic acid in the preparation of medicines for treating pathological jaundice. technical background [0002] Jaundice is a common clinical symptom, especially in the neonatal period. Due to its different pathogenesis, it can be both a physiological phenomenon and a pathological phenomenon. Among them, neonatal hemolytic disease, neonatal infection, biliary malformation, hepatitis and other diseases are the most common causes of pathological jaundice. According to different etiologies, pathological jaundice usually includes hemolytic jaundice, hepatocellular jaundice, and obstructive jaundice. Among them, hemolytic jaundice is due to the destruction of red blood cells in a short period of time, and the released bilirubin greatly exceeds the processing capacity of liver cells, resulting in jaundice. The increase of bilirubin in serum is dominated by indirec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/216A61P1/16
CPCA61K31/216
Inventor 张洁张梦甜黄望
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap